Literature DB >> 264783

Amphotericin B induction of sensitivity to adriamycin, 1,3-bis (2-chloroethyl)-1-nitrosourea (BCNU) plus cyclophosphamide in human neoplasia.

C A Presant, C Klahr, R Santala.   

Abstract

Seven patients with metastatic tumors resistant to therapy with adriamycin, BCNU, plus cyclophosphamide received the same chemotherapy combined with amphotericin B. One complete response (acute myelomonocytic leukemia), two partial responses (carcinoma of the breast and multiple myeloma), and one case with objective improvement (carcinoma of the breast) were observed in seven evaluable trials. Myelosuppression was not consistently changed by addition of amphotericin B. Fever and chills were common after amphotericin B. Bronchospasm and hypotension occurred twice. Amphotericin B reverses resistance to adriamycin-containing chemotherapy regimens in some patients.

Entities:  

Mesh:

Substances:

Year:  1977        PMID: 264783     DOI: 10.7326/0003-4819-86-1-47

Source DB:  PubMed          Journal:  Ann Intern Med        ISSN: 0003-4819            Impact factor:   25.391


  8 in total

1.  Modulation of macrophage tumoricidal capability by polyene antibiotics: support for membrane lipid as a regulatory determinant of macrophage function.

Authors:  H A Chapman; J B Hibbs
Journal:  Proc Natl Acad Sci U S A       Date:  1978-09       Impact factor: 11.205

Review 2.  Candida infection in surgical patients.

Authors:  J S Solomkin; R L Simmons
Journal:  World J Surg       Date:  1980-07       Impact factor: 3.352

Review 3.  Antineoplastic drugs: clinical pharmacology and therapeutic use.

Authors:  R A Bender; L A Zwelling; J H Doroshow; G Y Locker; K R Hande; D S Murinson; M Cohen; C E Myers; B A Chabner
Journal:  Drugs       Date:  1978-07       Impact factor: 9.546

4.  Effects of amphotericin B and its methyl ester on the antiviral activity of polyinosinic:polycytidylic acid.

Authors:  E C Borden; J A McBain; P H Leonhardt
Journal:  Antimicrob Agents Chemother       Date:  1979-08       Impact factor: 5.191

5.  Amphotericin B plus combination chemotherapy for extensive non-small cell bronchogenic carcinoma.

Authors:  G Sarna; B B Lowitz; P A Ganz; M J Cline
Journal:  Cancer Chemother Pharmacol       Date:  1980       Impact factor: 3.333

6.  Effects of amphotericin B on hepatitis B virus.

Authors:  H A Kessler; J Dixon; C R Howard; K Tsiquaye; A J Zuckerman
Journal:  Antimicrob Agents Chemother       Date:  1981-12       Impact factor: 5.191

7.  Conventional amphotericin B elicits markers of immunogenic cell death on leukemic blasts, mediates immunostimulatory effects on phagocytic cells, and synergizes with PD-L1 blockade.

Authors:  G Kofla; C Radecke; M Frentsch; W Walther; S Stintzing; H Riess; L Bullinger; I-K Na
Journal:  Oncoimmunology       Date:  2022-04-25       Impact factor: 7.723

8.  Potentiation of cis-diammine(1,1-cyclobutanedicarboxylato)platinum(II) by amphotericin B in BALB/c nude mice bearing human ovarian carcinoma cells.

Authors:  M Kojima; F Kikkawa; H Oguchi; K Tamakoshi; O Maeda; N Suganuma; Y Tomoda
Journal:  Jpn J Cancer Res       Date:  1994-11
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.